EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSLCAG00010025963
Gene Symbol: CACNA1E
1 Cross references
213 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSLCAG00010006026
Gene Symbol: CACNA1E
1 Cross references
206 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 H

Ensembl ID : ENSLCAG00010005311
Gene Symbol: CACNA1H
2 Cross references
211 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 H

Ensembl ID : ENSLCAG00010001146
Gene Symbol: CACNA1H
2 Cross references
211 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSLCAG00010021085
Gene Symbol: CNR1
4 Cross references
134 Possible Orthologues:

Cannabinoid Receptor 2

Ensembl ID : ENSLCAG00010003413
Gene Symbol: CNR2
1 Cross references
191 Possible Orthologues:

Cannabinoid Receptor Type 1a

Ensembl ID : ENSLCAG00010017690
Gene Symbol: LOC108873511
4 Cross references
149 Possible Orthologues:

Cannabinoid Receptor Type 1a

Ensembl ID : ENSLCAG00010014575
Gene Symbol: LOC108873511
4 Cross references
149 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSLCAG00010011366
Gene Symbol: CA12
4 Cross references
214 Possible Orthologues:

Carbonic Anhydrase 6

Ensembl ID : ENSLCAG00010005336
Gene Symbol: CA6
4 Cross references
215 Possible Orthologues:

Carbonic Anhydrase Iv A

Ensembl ID : ENSLCAG00010018657
Gene Symbol: CA4A
4 Cross references
212 Possible Orthologues:

Carbonic Anhydrase Iv B

Ensembl ID : ENSLCAG00010012338
Gene Symbol: CA4B
4 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).